SPM-0606

SPM-0606 is a preclinical, synthetic small molecule drug developed by Sea Pharmaceuticals. It acts as an antagonist at both the AMPA receptor and kainate receptor, which are subtypes of ionotropic glutamate receptors in the central nervous system. By inhibiting these excitatory neurotransmitter receptors, SPM-0606 aims to modulate glutamatergic signaling implicated in several neurological disorders. The drug is being investigated for potential use in treating amyotrophic lateral sclerosis (ALS), epilepsy, and tinnitus. Its mechanism targets excitatory glutamate neurotransmission with the goal of providing new therapeutic options for patients with CNS disorders where current treatments are limited or only modestly effective[1][2].